Last reviewed · How we verify
ALLOB® implantation
ALLOB® implantation is a Allogeneic cell therapy Small molecule drug developed by Bone Therapeutics S.A. It is currently in Phase 1 development.
Allogeneic osteoblastic cells that differentiate into bone-forming cells to promote bone regeneration at the site of implantation.
ALLOB implantation is being studied for its potential to treat various conditions, including Long Bone Delayed-Union Fracture, Failed Lumbar Fusion, Tibial Fracture, and Degenerative Disc Disease. The treatment involves the implantation of ALLOB, an allogeneic osteoblastic cell product, which is being investigated in clinical trials such as NCT02020590.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALLOB® implantation |
|---|---|
| Sponsor | Bone Therapeutics S.A |
| Drug class | Allogeneic cell therapy |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
ALLOB® contains allogeneic bone-forming cells that are implanted directly at the site of bone defects. These cells are designed to differentiate into mature osteoblasts and integrate into the bone matrix, promoting new bone formation and healing of skeletal defects.
Approved indications
Common side effects
Key clinical trials
- Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures (PHASE1, PHASE2)
- Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture (PHASE2)
- Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion (PHASE2)
- Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALLOB® implantation CI brief — competitive landscape report
- ALLOB® implantation updates RSS · CI watch RSS
- Bone Therapeutics S.A portfolio CI
Frequently asked questions about ALLOB® implantation
What is ALLOB® implantation?
How does ALLOB® implantation work?
Who makes ALLOB® implantation?
What drug class is ALLOB® implantation in?
What development phase is ALLOB® implantation in?
Related
- Drug class: All Allogeneic cell therapy drugs
- Manufacturer: Bone Therapeutics S.A — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing